CG Oncology (CGON) Assets Average (2024 - 2026)
CG Oncology's (CGON) quarterly Assets Average came in at $963.4 million in Q1 2026, up 29.93% YoY from $741.5 million in Q1 2025, and up 26.64% on a QoQ basis from $760.8 million in Q4 2025.
CG Oncology (CGON) Assets Average (2024 - 2026) Analysis & Trends
CG Oncology (CGON) has 3 years of Assets Average data on file, last reported at $963.4 million in Q1 2026.
- Quarterly Assets Average rose 29.93% year-over-year to $963.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $963.4 million (up 29.93% YoY) and the FY2025 annual result came in at $773.2 million, up 62.08% from the prior year.
- Assets Average climbed to $963.4 million in Q1 2026, from $760.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $963.4 million in Q1 2026 to a low of $389.2 million in Q1 2024.
- A 3-year average of $674.3 million and a median of $714.8 million in 2025 frame the typical range for Assets Average.
- The widest YoY moves for Assets Average: up 90.51% in 2025, down 16.39% in 2025.
- Tracing CGON's Assets Average over 3 years: stood at $653.6 million in 2024, then rose by 16.39% to $760.8 million in 2025, then advanced by 26.64% to $963.4 million in 2026.
- The last three Assets Average figures came in at $963.4 million (Q1 2026), $760.8 million (Q4 2025), and $715.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 1.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.11 Bn |
| Mar 31, 2026 | 963.43 Mn |
| Dec 31, 2025 | 760.75 Mn |
| Sep 30, 2025 | 715.68 Mn |
| Jun 30, 2025 | 714.81 Mn |
| Mar 31, 2025 | 741.49 Mn |
| Dec 31, 2024 | 653.63 Mn |
| Sep 30, 2024 | 558.40 Mn |
| Jun 30, 2024 | 571.72 Mn |
| Mar 31, 2024 | 389.20 Mn |